Elanco Animal Health Inc · Q3 2021 earnings

Briefing

Elanco exceeded revenue guidance and raised full year 2021 revenue guidance.

Elanco Animal Health reported a strong third quarter in 2021, exceeding top-line growth expectations for the fourth consecutive quarter. The company is making headway toward long-term margin targets, with pro forma combined company revenue expected to increase by approximately 7 percent and adjusted EBITDA margin expected to expand by approximately 300 basis points.

• Elanco's revenue was $1,131 million, benefiting from increased scale and diversification with the addition of Bayer Animal Health.
• On a pro forma combined company basis, Elanco's revenue grew approximately 6 percent.
• Products from the legacy Bayer Animal Health business contributed $421 million.
• Elanco has now launched all eight of the planned launches for 2021.

Headline financials

Revenue & EPS history

Elanco is updating its full year 2021 guidance for reported net loss and reported EPS to reflect third quarter results, which differed from the company's August guidance driven by two non-cash charges related to the R&D asset write-down and the settlement of the canine parvovirus license agreement. Reported EPS guidance continues to also incorporate a write-down of $0.47 per share from the exit of the three manufacturing sites announced on June 9, 2021. The company is raising its full year 2021 guidance for revenue and maintaining its full year 2021 guidance for adjusted EBITDA and adjusted earnings per share, as compared to the August 9 guidance communication, despite a higher than expected full year 2021 tax rate at approximately 24.5% than previously expected at approximately 24%. Additionally, Elanco is introducing guidance for the fourth quarter of 2021. The revenue range reflects management's expectation for consistent fundamental business performance.